Answer
Hepatotoxicity, hepatitis B reactivation, hepatitis E that may be chronic, and hepatic failure, including fatal events, have been reported in patients treated with Imbruvica (ibrutinib).
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 25Document updated
Sources checked